Evidence map›Paper›PMID 37506345›Full record

ArticleBlood2023

Cryo-EM structures of human arachidonate 12S-lipoxygenase bound to endogenous and exogenous inhibitors.

Jesse I Mobbs, Katrina A Black, Michelle Tran, Wessel A C Burger, Hariprasad Venugopal, Theodore R Holman, Michael Holinstat, David M Thal, Alisa Glukhova

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Activation and execution of lipoxygenase catalysis.Redox biochemistry and chemistry · 2026
    Article
  2. Allosteric properties of mammalian ALOX15 orthologs.The Journal of biological chemistry · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Antiplatelet strategies: past, present, and future.Journal of thrombosis and haemostasis : JTH · 2023
    Review
  10. Pass the 12-LOX!Blood · 2023
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jesse I MobbsDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID 0000-0001-6979-1427
Katrina A BlackStructural Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID 0000-0002-4094-6170
Michelle TranDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, CA.ORCID 0000-0002-7578-9347
Wessel A C BurgerARC Centre for Cryo-Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID 0000-0003-2047-2593
Hariprasad VenugopalRamaciotti Centre for Cryo-Electron Microscopy, Monash University, Clayton, VIC, Australia.ORCID 0000-0001-5230-2973
Theodore R HolmanDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, CA.ORCID 0000-0001-8072-2959
Michael HolinstatDepartment of Pharmacology, University of Michigan, Ann Arbor, MI.ORCID 0000-0001-5100-1933
David M ThalDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID 0000-0002-0325-2524
Alisa GlukhovaDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID 0000-0003-4146-965X
Monash University · AUThe University of Melbourne · AUUniversity of California, Santa Cruz · USUniversity of Michigan · US

Funding

12-HETrE regulation of blood coagulation, hemostasis, and thrombosisR35GM131835 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLINSTAT, MICHAEL ALLAN · 2019 to 2023
$2.3M
NIGMS NIH HHS R35 GM131835
6 · The paper itself

Abstract

Human 12-lipoxygenase (12-LOX) is a key enzyme involved in platelet activation, and the regulation of its activity has been targeted for the treatment of heparin-induced thrombocytopenia. Despite the clinical importance of 12-LOX, the exact mechanisms by which it affects platelet activation are not fully understood, and the lack of structural information has limited drug discovery efforts. In this study, we used single-particle cryo-electron microscopy to determine high-resolution structures (1.7-2.8 Å) of human 12-LOX. Our results showed that 12-LOX can exist in multiple oligomeric states, from monomer to hexamer, which may affect its catalytic activity and membrane association. We also identified different conformations within the 12-LOX dimer, which likely represent different time points in its catalytic cycle. Furthermore, we identified small molecules bound to 12-LOX. The active site of the 12-LOX tetramer was occupied by an endogenous 12-LOX inhibitor, a long-chain acyl coenzyme A. In addition, we found that the 12-LOX hexamer can simultaneously bind to arachidonic acid and ML355, a selective 12-LOX inhibitor that has passed a phase 1 clinical trial for the treatment of heparin-induced thrombocytopenia and received a fast-track designation by the Food and Drug Administration. Overall, our findings provide novel insights into the assembly of 12-LOX oligomers, their catalytic mechanism, and small molecule binding, paving the way for further drug development targeting the 12-LOX enzyme.

Indexed as

Platelet ActivationThrombocytopeniaArachidonate 12-LipoxygenaseArachidonic AcidCryoelectron MicroscopyHumansUnited StatesArachidonate 12-LipoxygenaseArachidonic Acid

Identifiers

PMID37506345
PMCPMC10579047
OpenAlexW4385334227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.